Azafaros
CompanyNetherlands
Azafaros develops one asset, in phase 3 (Nizubaglustat in GM1 and GM2 gangliosidoses). Mostly small molecule acting on lipid and ceramide metabolism, UGCG and GBA2; based in Netherlands.
- 1
- Asset
- Furthest stage
- Phase 3
- Raised
- €157m
- 0
- Trials
- 0
- Signals
Pipeline
1Brain-penetrant azasugar that interferes with glycosphingolipid metabolism through a dual mode of action.
Phase 3, Small molecule, Lipid and ceramide metabolism, UGCG, GM1 and GM2 gangliosidoses, GM2 gangliosidosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Funding rounds and grants2
- People8
- Signals1
- Similar companies6